Aster DM Healthcare Limited — PPTs, 30-07-2025: Investor Presentation

Here's a summary of the attached investor presentation:

**1. Financial Highlights:**

Aster's Q1 FY26 revenue grew 8% YoY to INR 1,078 Cr, with operating EBITDA up 21% to INR 215 Cr (20.0% margin). Normalised PAT rose 22%. Combined with Quality Care, total revenue hit INR 2,157 Cr and operating EBITDA INR 442 Cr (20.5% margin), showcasing strong ARPOB growth and improved debt ratios.

**2. Strategic Initiatives & Growth Drivers:**

The company plans to add 2,600+ beds, increasing total capacity to 7,800+, with a focus on Bangalore expansion. Digital initiatives like the Aster Health app are gaining traction with over 100K downloads. High-growth specialties like Oncology are prioritized. Operational efficiencies include QCIL's Nagercoil unit achieving quick breakeven.

**3. Business Developments:**

The Share Swap for the Quality Care merger is complete, with new shares listed. The full merger is expected by Q4 FY26. Strategic exits from certain loss-making pharmacy units improved overall profitability.

**4. Market Position & Competitive Advantage:**

Leadership is being strengthened in key markets like Bangalore, contributing to a combined 10,350+ bed capacity. High-end procedures (robotics, transplants) and efficient operations provide differentiation. Focus on clinical talent and optimized procurement also enhance competitive edge.

**5. Investor Implications:**

Robust financial performance, ambitious bed expansion plans, and anticipated merger synergies indicate strong growth potential. Operational efficiencies and digital initiatives support future profitability. Investors should monitor execution of large capital projects and merger integration.